Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, closed a €22m ($26m) series B round yesterday co-led by Vesalius BioCapital III and BioMedPartners.
All existing shareholders – EMBL Ventures, the investment arm of European Molecular Biology Laboratory, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical firm Boehringer Ingelheim’s Venture Fund and Gimv – participated.
Founded in 2003, Topas Therapeutics is working on therapies for autoimmune diseases. Its lead…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in